Drug Trial Radar · NCT03615326
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
738
Actual
Start
Oct 5, 2018
Primary completion
Mar 20, 2024
Study completion Nov 12, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Aug 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS).
Conditions
- Gastric Neoplasms
- Gastroesophageal Junction Adenocarcinoma
Interventions
PembrolizumabBiological
200 mg on Day 1 of each 3-week cycle as an IV infusion.
PlaceboBiological
Solution for IV infusion on Day 1 of each 3-week cycle.
CisplatinDrug
80 mg/m\^2 on Day 1 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen.
5-FUDrug
800 mg/m\^2/day continuous on Days 1-5 of each 3-week cycle (120 hours or per local standard), administered as part of FP chemotherapy regimen.
OxaliplatinDrug
130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen and as part of SOX chemotherapy regimen.
CapecitabineDrug
1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.
S-1Drug
Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX chemotherapy regimen.
TrastuzumabBiological
8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) Per RECIST 1.1 Assessed by BICRTime frame: Up to approximately 46 months
- Overall Survival (OS)Time frame: Up to approximately 63 months
Locations
192 sites in 20 countries. Site status is shown where the registry gives one.
UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0045)
Los Angeles, California
Pacific Cancer Care ( Site 0063)
Monterey, California
UC Irvine Medical Center/Chao Family Comprehensive Cancer Center ( Site 0050)
Orange, California
University of Miami Sylvester Comprehensive Cancer Center - Plantation ( Site 0026)
Miami, Florida
Southeastern Regional Medical Center, Inc. ( Site 0058)
Newnan, Georgia
Midwestern Regional Medical Center, Inc. ( Site 0059)
Zion, Illinois
Beth Israel Deaconess Medical Center ( Site 0070)
Boston, Massachusetts
Dana-Farber Cancer Institute [Boston, MA] ( Site 0010)
Boston, Massachusetts
Minnesota Oncology Hematology, PA ( Site 8001)
Minneapolis, Minnesota
Washington University School of Medicine ( Site 0040)
St Louis, Missouri
Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0071)
Middletown, New Jersey
Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 0065)
Harrison, New York
Memorial Sloan-Kettering Cancer Center ( Site 0017)
New York, New York
University of Rochester ( Site 0041)
Rochester, New York
Levine Cancer Institute ( Site 0015)
Charlotte, North Carolina
Duke Cancer Institute ( Site 0042)
Durham, North Carolina
CTCA Southwestern ( Site 0060)
Tulsa, Oklahoma
Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0025)
Philadelphia, Pennsylvania
Allegheny General Hospital ( Site 0053)
Pittsburgh, Pennsylvania
Sanford Hematology Oncology-Sioux Falls SD ( Site 0004)
Sioux Falls, South Dakota
University of Texas MD Anderson Cancer Center ( Site 0001)
Houston, Texas
Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 8000)
Roanoke, Virginia
Seattle Cancer Care Alliance ( Site 0038)
Seattle, Washington
Liverpool Hospital ( Site 2206)
Liverpool, New South Wales, Australia
Westmead Hospital ( Site 2200)
Westmead, New South Wales, Australia
Southern Medical Day Care Centre ( Site 2207)
Wollongong, New South Wales, Australia
Monash Health ( Site 2202)
Clayton, Victoria, Australia
Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0201)
Rio de Janeiro, Brazil
IBCC - Instituto Brasileiro de Controle do Cancer ( Site 0204)
São Paulo, Brazil
Instituto do Cancer do Ceara ( Site 0208)
Fortaleza, Ceará, Brazil
Hospital Sao Rafael ( Site 0209)
Salvador, Estado de Bahia, Brazil
CIONC - Centro Integrado de Oncologia de Curitiba ( Site 0205)
Curitiba, Paraná, Brazil
Hospital de Caridade de Ijui ( Site 0202)
Ijuí, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao ( Site 0203)
Porto Alegre, Rio Grande do Sul, Brazil
CEPON - Centro de Pesquisas Oncologicas ( Site 0200)
Florianópolis, Santa Catarina, Brazil
Centro Investigación del Cáncer James Lind ( Site 0300)
Temuco, Araucania, Chile
Clinica Universidad Catolica del Maule ( Site 0305)
Talca, Maule Region, Chile
Fundacion Arturo Lopez Perez FALP ( Site 0302)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 0301)
Santiago, Region M. de Santiago, Chile
Instituto Nacional del Cancer ( Site 0303)
Santiago, Region M. de Santiago, Chile
Showing 40 of 192 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.